Pharsight

1. Clenpiq patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624879	FERRING PHARMS INC	Liquid pharmaceutical composition	Jun, 2034 (10 years from now)
US11191753	FERRING PHARMS INC	Liquid pharmaceutical composition	Jun, 2034 (10 years from now)
US9827231	FERRING PHARMS INC	Liquid pharmaceutical composition	Jun, 2034 (10 years from now)

Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient

Market Authorisation Date: 28 November, 2017

Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy

Dosage: SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
10 mg, 3.5 g, and 12 g	11 Feb, 2019	1		26 Jun, 2034

Strength	Dosage	Availability
12GM/BOT;3.5GM/BOT;10MG/BOT	SOLUTION;ORAL	Prescription

CLENPIQ family patents

2. Milprosa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10537584	FERRING PHARMS INC	Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof	Feb, 2029 (5 years from now)
US10548904	FERRING PHARMS INC	Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof	Feb, 2029 (5 years from now)
US8580293	FERRING PHARMS INC	Monolithic intravaginal rings comprising progesterone and methods of making and uses thereof	Jan, 2030 (6 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Apr 29, 2023

Drugs and Companies using PROGESTERONE ingredient

Market Authorisation Date: 29 April, 2020

Treatment: Method of supporting embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women

Dosage: SYSTEM;VAGINAL

Strength	Dosage	Availability
1.78GM	SYSTEM;VAGINAL	Discontinued

MILPROSA family patents

3. Nocdurna patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP09751584A	2014-11-11	Gebro Pharma GmbH	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US9974826	April, 2015	Decision	Bjarke Mimer Klein et al

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10307459	FERRING PHARMS INC	Pharmaceutical formulations of desmopressin	May, 2023 (4 months ago)
US9220747	FERRING PHARMS INC	Methods using desmopressin acetate in orodispersible form	May, 2023 (4 months ago)
US9919025	FERRING PHARMS INC	Pharmaceutical formulations of desmopressin	May, 2023 (4 months ago)
US9504647	FERRING PHARMS INC	Pharmaceutical formulations of desmopressin	May, 2023 (4 months ago)
US8802624	FERRING PHARMS INC	Methods of treatment using orodispersible desmopressin pharmaceutical formulations	Dec, 2023 (2 months from now)
US7947654	FERRING PHARMS INC	Pharmaceutical formulations	Dec, 2023 (2 months from now)
US7560429	FERRING PHARMS INC	Orodispersible dosage forms of desmopressin acetate	Feb, 2024 (4 months from now)
US11020448	FERRING PHARMS INC	Methods comprising desmopressin	May, 2029 (5 years from now)
US10137167	FERRING PHARMS INC	Methods comprising desmopressin	May, 2029 (5 years from now)
US9974826	FERRING PHARMS INC	Methods comprising desmopressin	Apr, 2030 (6 years from now)

Drugs and Companies using DESMOPRESSIN ACETATE ingredient

Market Authorisation Date: 21 June, 2018

Treatment: Treatment of nocturia due to nocturnal polyuria in adults; Treatment of nocturia due to nocturnal polyuria in adults, comprising monitoring a patient's serum sodium concentration

Dosage: TABLET;SUBLINGUAL

Strength	Dosage	Availability
0.0277MG	TABLET;SUBLINGUAL	Prescription
0.0553MG	TABLET;SUBLINGUAL	Prescription

NOCDURNA family patents

4. Prepopik patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8481083	FERRING PHARMS INC	Granular compositions of magnesium oxide and citric acid and uses thereof	Oct, 2028 (5 years from now)
US8450338	FERRING PHARMS INC	Granular compositions of sodium picosulphate and potassium bicarbonate and uses thereof	Oct, 2028 (5 years from now)